Amgen Stock Clings to 52-Week High Despite Analyst Skepticism
Amgen Inc.'s stock price remained near its 52-week high on August 28, 2026, following the company's quarterly earnings release. The biotechnology giant reported revenue of $10.05 billion and adjusted EPS of $6.29 for Q2 2026, both exceeding estimates.
The results also led to an increase in Amgen's full-year 2026 guidance, with projected EPS now ranging from $22.30 to $23.50 per share. This improvement has positioned the stock above its consensus price target of $380.43 and supported a dividend yield of 2.3%.
One notable product within Amgen's portfolio is TEZSPIRE, which demonstrated positive Phase 3 results in eosinophilic esophagitis and has potential for growth beyond severe asthma. The company's market capitalization stands at $236.25 billion, with a 52-week range of $269.77 to $447.03.
The strong quarterly performance and favorable product pipeline have contributed to Amgen's stock price holding near its high point, despite a consensus recommendation of 'Hold' from analysts.